Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Parallel, 24-Week, Phase 2a Study of Topical Pirenzepine (WST-057) or Placebo in Type 2 Diabetic Patients With Peripheral Neuropathy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Dec 2022
Price :
$35
*
At a glance
- Drugs Pirenzepine (Primary)
- Indications Diabetic neuropathies
- Focus Adverse reactions; Proof of concept
- Sponsors WinSanTor
- 03 Mar 2022 Status changed from active, no longer recruiting to completed.
- 04 Aug 2021 Planned End Date changed from 1 Dec 2021 to 28 Jan 2022.
- 04 Aug 2021 Planned primary completion date changed from 1 Oct 2021 to 14 Jan 2022.